[Purpose] To evaluate the therapeutic results of Panitumumab (P-mab) treatment in 19 cases of unresectable advanced/recurrent colorectal cancer treated from December 2010 to March 2012 in our department.
[Method] The first, second, third, and fourth therapeutic lines included 3, 8, 6, and 2 cases respectively. According to the administration regimen, 13, 4, and 2 cases were treated with FOLFIRI + P-mab, mFOLFOX7 + P-mab, and P-mab alone, respectively.
[Results] The therapeutic outcomes were complete response, partial response, stable disease, progressive disease, and not evaluated in 0, 1, 2, 12, and 4 cases, respectively. The response rate was 5.3%, and the tumor control rate was 15.8%. The median survival time was 9.74 months. Skin toxicity, infusion reaction, hypomagnesemia, and persistent dizziness were seen in 7 (G1: 3 cases, G3: 4 cases), 1, 1, and 1 case, respectively.
[Conclusion] The therapeutic results of P-mab were not necessarily good. Additionally, skin toxicity associated with anti-epidermal growth factor receptor monoclonal antibodies occurred frequently. Skin toxicity considerably reduce the quality of life of patients and might result in decreased drug compliance. Therefore, close follow-up not only by the outpatient physician but also through collaboration with dermatologists, pharmacists and nurses is considered necessary.
View full abstract